OHSU Knight Cancer Institute
- World rank, all time
- #26,009 of 42,892
- Rank in ??
- #451 of 1,041
- Research works
- 177 ▲ 56% vs 2013–17
- Citations
- 4k 22.8 per fractional work
- Top-10% rate
- 12.9% record average 16.5%
- Open access
- 36% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 4.7×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 4.7×
- Immunology and Microbiology 3.1×
- Medicine 3.0×
- Veterinary 0.9×
- Economics, Econometrics and Finance 0.9×
- Health Professions 0.9×
- Nursing 0.6×
- Chemistry 0.5×
- Pharmacology, Toxicology and Pharmaceutics 0.4×
- Dentistry 0.4×
- Engineering 0.2×
- Social Sciences 0.2×
- Computer Science 0.1×
- Materials Science 0.1×
- Neuroscience 0.1×
- Business, Management and Accounting 0.1×
- Physics and Astronomy 0.1×
- Environmental Science 0.1×
- Psychology 0.1×
- Agricultural and Biological Sciences 0.0×
Which keywords describe research at OHSU Knight Cancer Institute?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Immunotherapy, Prognostic Factors, Chemotherapy, Targeted Therapy, Tumor Microenvironment, Genomic Instability, Cancer Genomics and Mutational Signatures.
- Survival Analysis
- Homologous Recombination
- Cancer Immunotherapy
- Prostate Cancer
- Management
- Hormone Therapy
- Surgical Complications
- Genomic Profiling
- Immune Checkpoint Blockade
- Cancer
- Precision Medicine
- Quality of Life
- Genetic Mutations
- Neoadjuvant Therapy
- Gene Expression
- Cancer Therapy
- Mutational Signatures
- Genomic Instability
- Targeted Therapy
- Prognostic Factors
- Immunotherapy
- Chemotherapy
- Tumor Microenvironment
- Cancer Genomics
- Clinical Practice Guidelines
- Clinical Trials
- Treatment
- Biomarkers
- PET Imaging
- Breast Cancer
- Surgical Management
- Diagnosis
- PD-1 and PD-L1
- Pancreatic Cancer
- Androgen Receptor
- Imatinib Mesylate
- PDGFRA Mutations
- Sunitinib
- Hepatocellular Carcinoma
- Regenerative Medicine
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Immunotherapy4▲ 14×12 topics
- Prognostic Factors4▲ 21×11 topics
- Chemotherapy4▲ 13×12 topics
- Targeted Therapy4▲ 36×5 topics
- Tumor Microenvironment3▲ 17×6 topics
- Genomic Instability3▲ 62×2 topics
- Cancer Genomics3▲ 86×1 topic
- Mutational Signatures3▲ 86×1 topic
- Clinical Practice Guidelines2▲ 10×5 topics
- Cancer Therapy2▲ 8.2×7 topics
- Clinical Trials2▲ 7.2×9 topics
- Gene Expression2▲ 7.7×5 topics
- Treatment2▲ 3.8×6 topics
- Neoadjuvant Therapy2▲ 18×4 topics
- Biomarkers2▲ 5.9×6 topics
- Genetic Mutations2▲ 9.2×9 topics
- PET Imaging2▲ 23×4 topics
- Quality of Life2▲ 2.6×8 topics
- Breast Cancer2▲ 14×5 topics
- Precision Medicine2▲ 7.3×4 topics
- Surgical Management2▲ 8.5×2 topics
- Cancer1▲ 2.3×14 topics
- Diagnosis1▲ 3.3×5 topics
- Immune Checkpoint Blockade1▲ 29×1 topic
- PD-1 and PD-L11▲ 29×1 topic
- Genomic Profiling1▲ 28×2 topics
- Pancreatic Cancer1▲ 25×1 topic
- Surgical Complications1▲ 34×1 topic
- Androgen Receptor1▲ 33×1 topic
- Hormone Therapy1▲ 29×1 topic
- Imatinib Mesylate1▲ 48×2 topics
- Management1▲ 3.1×4 topics
- PDGFRA Mutations1▲ 87×1 topic
- Prostate Cancer1▲ 20×2 topics
- Sunitinib1▲ 87×1 topic
- Cancer Immunotherapy1▲ 15×3 topics
- Hepatocellular Carcinoma1▲ 11×2 topics
- Homologous Recombination1▲ 51×2 topics
- Regenerative Medicine1▲ 9.2×4 topics
- Survival Analysis1▲ 8.4×5 topics
Which research topics does OHSU Knight Cancer Institute publish most on?
By volume in 2022–2025: Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research and Prostate Cancer Treatment and Research.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Genomics and Diagnostics Cancer Research 3 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 3 Pancreatic and Hepatic Oncology Research Oncology 1 works
- 4 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 1 works
- 5 Gastrointestinal Tumor Research and Treatment Gastroenterology 1 works
- 6 Single-cell and spatial transcriptomics Molecular Biology 1 works
- 7 Hepatocellular Carcinoma Treatment and Prognosis Hepatology 1 works
- 8 Sarcoma Diagnosis and Treatment Pulmonary and Respiratory Medicine 1 works
- 9 PARP inhibition in cancer therapy Oncology 1 works
- 10 Epigenetics and DNA Methylation Molecular Biology 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has OHSU Knight Cancer Institute's research output changed?
Output in 2018–2022 was 56% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Portland
- Daimler Truck (United States)
- Pacific States Marine Fisheries Commission
- Oregon Water Science Center
- Western Wildland Environmental Threat Assessment Center
- Center for Process Studies
- FluxMagic, Inc. (United States)
- Lemelson Foundation
- Avangrid Renewables
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.